Tuesday, December 22, 2009 7:23:19 AM
Back from when I followed OMRI until it was munched by JNJ
Thrombin stand-alone is intended for cases, such as certain types of neurosurgery, where the physician desires a more gradual onset of clotting than that provided by standard fibrin sealants. OMRI expected that the standalone thrombin market over time will remain flat or decrease in favor of thrombin-enhanced hemostats (including flowables). OMRI also expected fibrin patch to be the next big thing (I also got positive comments at that time from a trauma surgeon on the broad utility for the product).
Edit: just found this slide from OMRI's presentation on convergence product
Thrombin stand-alone is intended for cases, such as certain types of neurosurgery, where the physician desires a more gradual onset of clotting than that provided by standard fibrin sealants. OMRI expected that the standalone thrombin market over time will remain flat or decrease in favor of thrombin-enhanced hemostats (including flowables). OMRI also expected fibrin patch to be the next big thing (I also got positive comments at that time from a trauma surgeon on the broad utility for the product).
Edit: just found this slide from OMRI's presentation on convergence product
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
